Prostate cancer immunotherapy trial halted early: what we know

NCT ID NCT05617040

First seen Nov 10, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This early-stage trial tested an experimental immunotherapy called VTP-850 in 22 men whose prostate cancer had returned after initial treatment like surgery or radiation. The goal was to check safety and see if the treatment could lower PSA levels, a marker of cancer activity. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina, 29572, United States

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

  • Cornell University

    New York, New York, 10065-4805, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • University of Virginia Health System

    Charlottesville, Virginia, 22908, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.